Study of Durvalumab following radiation therapy in patients with stage 3 unresectable NSCLC ineligible for chemotherapy - DUART

Study identifier:D4194C00009

ClinicalTrials.gov identifier:NCT04249362

EudraCT identifier:2019-004336-31

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemotherapy

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Durvalumab

Sex

All

Actual Enrollment

102

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 26 Nov 2020
Primary Completion Date: 30 Mar 2023
Estimated Study Completion Date: 31 Oct 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria